The sale of Elanco's aqua business to Merck Animal Health for $1.3 billion is a significant transaction that is likely to be viewed positively by investors. This influx of cash could be used for debt reduction, reinvestment in core areas, or shareholder returns, all of which can contribute to a positive outlook on ELAN's stock in the short term.